"As commercial adoption of the Evolut R System increases, it's important that we work in collaboration with heart teams to offer this advanced, next-generation device that helps provide clinical improvements in 'real-world' patient populations," said Rhonda Robb, vice president and general manager of the Heart Valve Therapies business, a part of Medtronic's Cardiac and Vascular Group. "The latest FORWARD and TVT Registry results presented today further builds upon the growing body of global evidence supporting our self-expanding TAVR systems as safe and effective treatment options."

Built on the proven foundation and procedural success of the CoreValve System, which has been implanted in more than 100,000 patients in 60 countries, the CoreValve Evolut R System is available in Europe and other countries that recognize the CE (Conformité Européene) Mark and was approved for commercial use in the United States in 2015.


In collaboration with leading clinicians, researchers and scientists worldwide, Medtronic offers the broadest range of innovative medical technology for the interventional and surgical treatment of cardiovascular disease and cardiac arrhythmias. The company strives to offer products and services that deliver clinical and economic value to healthcare consumers and providers around the world.


About Medtronic
Medtronic plc (www.medtronic.com), headquartered in Dublin, Ireland, is among the world's largest medical technology, services and solutions companies - alleviating pain, restoring health and extending life for millions of people around the world. Medtronic employs more than 88,000 people worldwide, serving physicians, hospitals and patients in more than 160 countries. The company is focused on collaborating with stakeholders around the world to take healthcare Further, Together.

Back to HCB News

Cardiology Homepage